Table 1 Univariate analysis of clinical factors and SE-associated genes for overall survival and lung metastasis-free survival
|  | OS (Training Set, n = 159) | LMFS (Training Set, n = 141) | ||||
|---|---|---|---|---|---|---|
Hazard Ratio | 95% CI of ratio | p-value | Hazard Ratio | 95% CI of ratio | p-value | |
Gender (female vs male) | 1.33 | 0.87 to 2.03 | 0.20 | 1.13 | 0.68 to 1.86 | 0.65 |
Age (< 18y vs ≥ 18y) | 1.04 | 0.68 to 1.59 | 0.88 | 1.01 | 0.61 to 1.67 | 0.99 |
Primary Site (extremities vs non-extremities) | 1.90 | 0.73 to 4.97 | 0.077 | 1.88 | 0.62 to 5.64 | 0.13 |
Histological Type | – | – | 0.37 | – | – | 0.60 |
Enneking Stage (I/II vs III) | 4.56 | 1.63 to 12.75 |  < 0.0001 | – | – | – |
Tumor Size (≤ 8 cm vs > 8 cm) | 1.84 | 1.20 to 2.81 | 0.0040 | 3.08 | 1.89 to 5.04 |  < 0.0001 |
Surgery Type (amputation vs limb sparing) | 0.64 | 0.40 to 1.03 | 0.041 | 0.52 | 0.30 to 0.91 | 0.0096 |
ALP (< 110/150 vs ≥ 110/150) | 2.09 | 1.34 to 3.25 | 0.0051 | 2.36 | 1.41 to 3.94 | 0.0056 |
LDH (< 240 vs ≥ 240) | 1.35 | 0.87 to 2.11 | 0.16 | 1.02 | 0.60 to 1.73 | 0.95 |
LACTB (low vs high expression) | 2.59 | 1.41 to 4.77 | 0.032 | – | – | – |
CEP55 (low vs high expression) | 1.76 | 1.10 to 2.83 | 0.042 | 1.82 | 1.05 to 3.15 | 0.067 |
SRSF3 (low vs high expression) | 2.70 | 1.54 to 4.73 | 0.014 | 2.44 | 1.27 to 4.67 | 0.047 |
TCF7L2 (low vs high expression) | 2.39 | 1.32 to 4.35 | 0.0001 | 1.86 | 0.90 to 3.83 | 0.037 |
FOXP1 (low vs high expression) | 2.60 | 1.35 to 5.03 |  < 0.0001 | 1.84 | 0.95 to 3.57 | 0.028 |
APOLD1 (low vs high expression) | – | – | – | 2.07 | 0.88 to 4.85 | 0.025 |
DNAJB12 (low vs high expression) | – | – | – | 1.59 | 0.97 to 2.59 | 0.067 |